Clinical Trial Limits Must Be Acknowledged In ADR Debate - FDA's Lumpkin
Executive Summary
Reform of the pharmaceutical adverse event monitoring system must be based on a larger debate over the societal expectations for clinical research, Center for Drug Evaluation & Research Deputy Director Murray Lumpkin, MD, told a Drug Information Association/ General Accounting Office panel Feb. 24 in Washington, D.C.